Author:
Khan Mohammad Mojeeb Gulzar,Deshmukh Mohammad Faizan Saadique,Firke Sandip Dinkar,Wahab Abdul Talib Abdul,Kalaskar Mohan Ganpatrao,Shirkhedkar Atul Arun
Abstract
Abstract
Background
Mifepristone is progestational and glucocorticoid hormone antagonist. The objective of this study is to develop simple and economical stability indicating RP-HPLC method for the determination of mifepristone in bulk and tablet formulation.
Result
The chromatographic separation was achieved on Qualisil BDS C8 column with mobile phase containing of mixture of Buffer (Potassium dihydrogen ortho phosphate, pH to 3.0 with ortho phosphoric acid) and Organic Solvent (Acetonitrile) 60:40 v/v pumped at flow rate 0.6 mL min−1. The detection of elute was performed using PDA detector at 305 nm. Mifepristone was eluted at 8.67 min. According to international conference on harmonization Q2(R1) guideline, method was validated and shows satisfactory results for accuracy, precision, linearity, ruggedness, robustness, detection limit, quantitation limit. The method indicated to be linear in the series of concentration 3–18 µg mL−1, and correlation coefficient was 0.9997. In acidic, basic, oxidative, thermal, photolytic forced degradation conditions, the peak of degradation product was clearly and well separated from drug peak without any interference in quantitative analysis. This represents stability indicating nature of established method.
Conclusion
The established RP-HPLC method is simple, accurate, specific, precise, robust, rugged, sensitive, and economical in nature which can be utilized for routine analysis of mifepristone in bulk and pharmaceutical formulation.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. The Merck Index (2006) An encyclopedia of chemicals, drugs, and biological, 14th edn. Merk & Co., Inc, Whitehouse Station, p 129
2. Indian Pharmacopoeia (2014) Government of India Ministry of Health and Family Wealthfare. The Indian Phamacopoeial Commission, II, Ghaziabad, pp 1090–1094
3. http://www.drugbank.ca/drugs/DBO1609
4. Duan X, Ning M (2015) Development and in vitro/in vivo evaluation of a silastic intra vaginal ring for mifepristone delivery. Indian J Pharm Sci 77(3):335–342
5. Yamsani N, Shravani A, Prathima S (2016) Analytical method development and validation for the simultaneous estimation of mifepristone and misoprostol in bulk and pharmaceutical dosage form by RP-HPLC. Int J Chem Pharm Anal 3(1):1–10